Abstract 14P
Background
Under the deep inspiration breath hold (DIBH) technique a considerable volume of the heart can be reduced to the high radiation doses. To investigate whether implementing DIBH to the hybrid technique will further reduce the cardiac doses, we compared the dosimetry characteristics of hybrid and VMAT treatment planning under DIBH and free breath.
Methods
Twenty patients with left-sided breast cancer who underwent breast-conserving surgery were selected for this study. Two sets of CT images were already acquired under deep-inspiration breath-hold (DIBH) and free-breathing(FB) before treatment. The same contours based on the original DIBH CT data sets were used for the modified Hybrid-technique and VMAT technique re-planning for the comparison of the original Hybrid planning. All plans were optimized to cover 100% of the PTV by 95% of the prescribed dose while minimizing the doses to the OAR as much as possible. The dosimetric differences among the 3 treatment plans for the 20 patients were analyzed using the Wilcoxon signed-rank test, the p value<0.05 were considered statistically significant. All analyses were performed using SPSS software, version 19.0.
Results
The mean heart dose was reduced from 3.2Gy and 5.38Gy, respectively (p value=0.002) and the LAD0.03cc dose was reduced from 14.85Gy and 24.91Gy, respectively (p value=0.001) by modified Hybrid-technique on DIBH and FB conditions. No statistically significant dose difference (p value>0.05) was found in the tumor conformity and homogeneity, and the critical organ on the affected side by the modified Hybrid-technique of VMAT under DIBH. In the contralateral critical organ, the modified Hybrid-tech showed better dose sparing than VMAT on the average dose of the contralateral lung, and the average dose of the contralateral breast.
Conclusions
Modified Hybrid-technique provides the best benefits for heart and OAR radiation dose sparing effect on DIBH condition.
Clinical trial identification
This clinical trial is approved by the institution review board of Taichung Veterans General Hospital (CE21447B).
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
17P - Clinical, pathological complete response and prognosis characteristics of HER2-low breast cancer in neoadjuvant chemotherapy setting: A retrospective analysis
Presenter: Hui Liu
Session: Poster viewing 01
18P - Low levels of miR-18a is associated with immunosuppression and increased chemo-unresponsiveness in ER-negative tumors
Presenter: Madhumathy Nair
Session: Poster viewing 01
19P - Cardiac and lung sparing radiotherapy in breast and chest wall irradiation with surface guided radiotherapy using deep inspiratory breath hold technique
Presenter: Ravi Shankar Bellala
Session: Poster viewing 01
20P - Physician perceptions to use of trastuzumab in HER2+ breast cancer in India
Presenter: Nagendra Ramanjinappa
Session: Poster viewing 01
23P - Combination chemotherapy and hormone therapy (CHT) in patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): A single-centre retrospective analysis
Presenter: Kripa Bajaj
Session: Poster viewing 01
24P - Outcomes of patients with HER2 positive metastatic breast cancer treated with low dose or metronomic lapatinib
Presenter: Sherin Mathew
Session: Poster viewing 01
25P - Absolute lymphocyte count as prognostic factor in patients with metastatic breast cancer: A systematic review and meta-analysis
Presenter: Dhea Hermanto
Session: Poster viewing 01
26P - Circulating osteocalcin-positive cells, as a novel biomarker for monitoring the therapeutic effects on bone metastasis
Presenter: Min Joo Kim
Session: Poster viewing 01
27P - Outcomes analysis of the effect of an educational activity on the knowledge and confidence of oncologists regarding emerging antibody drug conjugates for the treatment of breast cancer
Presenter: Nabil Dorkhom
Session: Poster viewing 01
28P - Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu-expressing breast cancer patients
Presenter: Yogesh Rathore
Session: Poster viewing 01